- Home
- PPBT vs CERO Comparison
PPBT vs CERO Comparison
Compare PPBT & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- CERO
- Stock Information
- Founded
- PPBT 2010
- CERO 2017
- Country
- PPBT Israel
- CERO United States
- Employees
- PPBT N/A
- CERO N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- CERO
- Sector
- PPBT Health Care
- CERO
- Exchange
- PPBT Nasdaq
- CERO Nasdaq
- Market Cap
- PPBT 8.7M
- CERO 8.4M
- IPO Year
- PPBT N/A
- CERO N/A
- Fundamental
- Price
- PPBT $2.73
- CERO $1.00
- Analyst Decision
- PPBT Strong Buy
- CERO
- Analyst Count
- PPBT 1
- CERO 0
- Target Price
- PPBT $33.00
- CERO N/A
- AVG Volume (30 Days)
- PPBT 16.9K
- CERO 183.5K
- Earning Date
- PPBT 03-10-2025
- CERO 03-18-2025
- Dividend Yield
- PPBT N/A
- CERO N/A
- EPS Growth
- PPBT N/A
- CERO N/A
- EPS
- PPBT N/A
- CERO N/A
- Revenue
- PPBT N/A
- CERO N/A
- Revenue This Year
- PPBT N/A
- CERO N/A
- Revenue Next Year
- PPBT N/A
- CERO N/A
- P/E Ratio
- PPBT N/A
- CERO N/A
- Revenue Growth
- PPBT N/A
- CERO N/A
- 52 Week Low
- PPBT $2.00
- CERO $1.26
- 52 Week High
- PPBT $20.60
- CERO $376.00
- Technical
- Relative Strength Index (RSI)
- PPBT 36.04
- CERO 29.16
- Support Level
- PPBT $2.61
- CERO $1.26
- Resistance Level
- PPBT $3.00
- CERO $1.54
- Average True Range (ATR)
- PPBT 0.21
- CERO 0.14
- MACD
- PPBT -0.01
- CERO 0.07
- Stochastic Oscillator
- PPBT 5.29
- CERO 1.63
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.